why choose us

First received: July 18, 2023

Clinical Trial: De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Kidney Transplant; Complications
CMV

Study Type: INTERVENTIONAL


Official Title: Historical Controlled, Single Center Open Label Pilot Comparing the Effectiveness and Tolerability of De-novo Initiation of Letermovir Versus Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidne

Brief Summary: This study is being done to compare the effectiveness of de novo Letermovir versus valganciclovir in preventing the development of cytomegalovirus viremia or symptomatic disease in African American kidney transplant recipients within the first year after transplantation.There are two arms in the study:Arm 1: Prophylaxis: This group includes freshly transplanted high risk (CMV D+/R-) African American Kidney recipients who will be on prophylactic Letermovir for 6 month.Arm 2: Prophylaxis: This group includes…

Read more